NCT05463432View on ClinicalTrials.gov

A Study of HR19024 in Subjects With Advanced Solid Tumor

PHASE1CompletedINTERVENTIONAL

Enrollment

71

Participants

Timeline

Start Date

August 10, 2022

Primary Completion Date

October 22, 2024

Study Completion Date

October 22, 2024

Conditions

Advanced Solid Tumor

Interventions

DRUG

HR19024

Intravenous infusion

Trial Locations (1)

200032

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

lead

Shanghai Hengrui Pharmaceutical Co., Ltd.

INDUSTRY